Multi-Organ Denervation With the iRF System to RedUce Sympathetic Drive

Hypertension Clinical Trial

— MODUS  

Official title:

Multi-Organ Denervation to RedUce Sympathetic Drive, Multi-Center, Prospective Feasibility Study - The MODUS ON MED Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04917393
• Other study ID #: 2040
• Status: Recruiting
• Phase: N/A
• Start date: September 13, 2021
• Est. completion date: October 1, 2023

Study information

• Verified date: June 2022
• Source: Metavention
• Contact: Adam Ahlstrom
• Phone: 1-612-814-8208
• Email: aahlstrom[@]metavention.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to evaluate the safety of multi-organ denervation using the Integrated Radio Frequency (iRF) Denervation System. and to understand any potential improvement in hypertension and glycemic control.

Description:

This study is a prospective, single-arm, multi-center, sham contollred trial to evaluate the initial safety and performance of multi-organ denervation for the treatment of hypertension and type 2 diabetes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: October 1, 2023
• Est. primary completion date: October 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Age = 18 and = 80 years old

2. Office systolic blood pressure (SBP) = 135 mmHg or on a stable dose of antihypertensive medication(s) for at least 30 days

3. Documented daytime systolic ambulatory blood pressure (ABP) = 135 and < 175 mmHg

4. HbA1c =7.5% - =11.0% on a stable dose of antidiabetic medication(s) for at least 90 days

5. Waist circumference = 102 cm (male) and = 88 cm (female)

Exclusion Criteria:

6. Renal artery (RA) anatomy on either side OR common hepatic artery (CHA) anatomy, ineligible for treatment including the following:

1. CHA OR RA artery diameter < 4.0 mm or > 7.0 mm

2. CHA or RA length that does not allow adequate landing zone for at least one iRF balloon placement and treatment

3. Only one functioning kidney

4. Presence of abnormal kidney tumors

5. CHA or RA with aneurysm

6. Pre-existing stent or history of angioplasty in target arteries

7. Fibromuscular dysplasia of the CHA or renal arteries

8. Presence of CHA OR RA diameter stenosis >30%

9. Individual lacks appropriate arterial anatomy for treatment or for maneuvering of the device from the femoral artery to the target location(s)

7. Prior renal denervation procedure

8. Type 1 diabetes mellitus

9. Use of insulin within 90 days prior to Index Procedure

10. eGFR < 45 mL/min per 1.73 m2

11. One or more documented severe hypertensive crisis (persistent or elevated hypertension > 180 mmHg accompanied by clinical symptoms) in the 90 days prior to Index Procedure

12. One or more documented hyperglycemia episodes (requiring hospitalization) in the 90 days prior to Index Procedure

13. One or more Severe hypoglycemic events (severe cognitive impairment requiring external assistance for recovery) in the 90 days prior to Index Procedure

14. Evidence of active infection within 7 days prior to Index Procedure

15. Documented history of chronic active inflammatory bowel disorders such as Crohn's disease or ulcerative colitis

16. Any history of cerebrovascular event (e.g., stroke, transient ischemic event, and cerebrovascular accident) within 6 months prior to Index Procedure

17. Myocardial infarction within 6 months of Index Procedure

18. Heart failure (New York Heart Association [NYHA] Class III-IV) at time of consent.

19. Documented confirmed episode(s) of stable or unstable angina within 6 months prior to Index Procedure

20. Documented history of persistent or permanent atrial tachyarrhythmia

21. Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea

22. Night shift workers

23. Chronic regular use (e.g., daily use) of NSAIDs for 6 months or greater. Aspirin therapy is allowed.

24. Active implantable medical device (e.g., ICD or CRT-D, neuromodulator/spinal stimulator, baroreflex stimulator)

25. Known Primary pulmonary hypertension (HTN) (> 60 mmHg pulmonary artery or right ventricular systolic pressure)

26. Individual has known pheochromocytoma, Cushing syndrome, primary hyperaldosteronism, coarctation of the aorta, untreated hyperthyroidism, untreated hypothyroidism, or primary hyperparathyroidism. (Note: Treated hyperthyroidism and treated hypothyroidism are permissible.)

27. A history of bariatric surgery, baroreflex activation therapy, or liver transplant, or these procedures are planned in the 365 days following Index Procedure

28. Previous hepatobiliary surgery/intervention that in the opinion of the investigator could preclude the ability to perform denervation of the CHA

29. History or diagnosis of proliferative retinopathy or advanced autonomic neuropathy (e.g., orthostatic hypotension attributable to autonomic neuropathy, a diagnosis of gastroparesis, or a clinical history strongly suggestive of delayed gastric emptying)

30. ALT or AST greater than 200 U/L

31. History or evidence of active / suspected chronic liver or biliary disease including Hepatitis B, Hepatitis C, autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis, Wilson's disease, alpha-1-antitrypsin deficiency, hemochromatosis, drug-induced liver disease, bile duct dilation and obstruction, symptomatic gallstones, liver cancer or liver cirrhosis. Note: subjects with past symptomatic gallstones and a cholecystectomy are not excluded.

32. Current or chronic pancreatitis

33. Documented contraindication or allergy to contrast medium not amenable to treatment

34. Limited life expectancy of < 1 year at the discretion of the investigator

35. Any known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or for any reason in the opinion of the investigator, would be unlikely or unable to comply with study protocol requirements or whose participation may result in data analysis confounders

36. Pregnant, nursing, or planning to become pregnant (documented negative pregnancy test result required documented within a maximum of 7 days before Index Procedure for all women of childbearing potential)

37. Concurrent enrollment in any other investigational drug or device trial (participation in noninterventional registries is acceptable)

Related Conditions & MeSH terms

• Hypertension
• Metabolic Syndrome
• Type 2 Diabetes

Intervention

Device:
• iRF System Multi-organ Denervation
If assigned to the treatment arm, subjects will remain blinded and recieve angiography prior to catheter based RF ablation to circumferentially disrupt the sympathetic nerves surrounding the target arteries

Other:
• Control Procedure
If assigned to the control group, subjects will remain blinded and recieve angiography of the target arteries prior to sheath removal.

Locations

Country	Name	City	State
Georgia	Israeli-Georgian Medical Research Clinic Helsicore	Tbilisi
Georgia	Tbilisi Heart and Vascular Clinic	Tbilisi

Sponsors (1)

Lead Sponsor	Collaborator
Metavention

Country where clinical trial is conducted

Georgia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of SADEs	The primary safety endpoint is the incidence rate of serious adverse device effects (SADEs)	Index Procedure through 30 days.
Secondary	Change in automated unobserved average office blood pressure	Change from baseline in systolic/diastolic blood pressure as indicated by average automated unobserved office blood pressure	90, 180 and 365 days
Secondary	Change in Systolic/Diastolic Blood Pressure - Ambulatory Blood Pressure Monitoring	Change from baseline in systolic/diastolic blood pressure as indicated by ambulatory blood pressure monitoring	90, 180 and 365 days
Secondary	Change in Glycemic control - HbA1c	Change from baseline in HbA1c percent	90 days, 180 days and 365 days
Secondary	Change in Glycemic control - fasting glucose	Change from baseline in fasting plasma glucose	90 days, 180 days and 365 days